DRRX 1.93 ▼ -0.52% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    DURECT Corporation

    NASDAQ: DRRX · Real-Time Price · USD
    1.93
    -0.01 (-0.52%)
    At close: Sep 04, 2025, 11:11 AM
    -0.52%
    Bid 1.92
    Market Cap 59.78M
    Revenue (ttm) 3.15M
    Net Income (ttm) -3.48M
    EPS (ttm) -0.43
    PE Ratio (ttm) -4.48
    Forward PE -2.77
    Analyst n/a
    Ask 1.93
    Volume 425,605
    Avg. Volume (20D) 1,086,227
    Open 1.92
    Previous Close 1.94
    Day's Range 1.91 - 1.93
    52-Week Range 0.48 - 2.64
    Beta 0.84

    About DRRX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol DRRX
    Website n/a
    Full Company Profile

    Next Earnings Release

    DURECT Corporation is scheduled to release its earnings on Nov 12, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    +240.15%
    DURECT shares are trading higher after announcing ... Unlock content with Pro Subscription
    news image

    1 week ago · accessnewswire.com

    Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

    LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ:DRRX) t...

    news image

    3 weeks ago · zacks.com

    Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates

    Durect (DRRX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.12 per share a year ago.

    news image

    1 month ago · benzinga.com

    Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

    Bausch Health Companies Inc. BHC on Tuesday agreed to indirectly acquire DURECT Corp DRRX, including a novel therapeutic molecule, larsucosterol.

    news image

    1 month ago · businesswire.com

    DRRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DURECT Corporation Is Fair to Shareholders

    NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of DURECT Corporation (NASDAQ: DRRX) to Bausch Health Companies Inc. for $1.75 per share is ...

    news image

    1 month ago · businesswire.com

    Shareholder Alert: The Ademi Firm Investigates Whether DURECT Corporation Is Obtaining a Fair Price for Its Public Shareholders

    MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating DURECT (NYSE: DRRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bausch Health. Click here to...

    news image

    1 month ago · accessnewswire.com

    Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

    DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option for the treatment of patients with al...

    Add to Watchlist